Esperion Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Esperion Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2012 to Q3 2024.
  • Esperion Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$29.5M, a 28.4% increase year-over-year.
  • Esperion Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$86.8M, a 58.4% increase year-over-year.
  • Esperion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$209M, a 10.4% increase from 2022.
  • Esperion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$234M, a 13.2% increase from 2021.
  • Esperion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$269M, a 87.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$86.8M -$29.5M +$11.7M +28.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$98.5M -$61.9M -$12M -24% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$86.5M $61M +$123M Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$209M -$56.3M -$857K -1.55% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$208M -$41.3M +$13.9M +25.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$222M -$49.9M +$16.4M +24.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$239M -$61.7M -$4.99M -8.79% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$234M -$55.5M +$9.63M +14.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$243M -$55.1M +$14.3M +20.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$258M -$66.3M -$22.7M -51.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$235M -$56.7M +$34.2M +37.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$269M -$65.1M +$39.4M +37.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-21
Q3 2021 -$308M -$69.4M +$16.1M +18.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 -$325M -$43.7M -$168M -135% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-01
Q1 2021 -$156M -$90.9M -$12.7M -16.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-01
Q4 2020 -$144M -$104M -$42.5M -68.7% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-23
Q3 2020 -$101M -$85.4M -$17.1M -25% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$84M $125M +$179M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-02
Q1 2020 -$263M -$78.2M -$166M -190% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-02
Q4 2019 -$97.2M -$61.9M -$1.91M -3.18% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-23
Q3 2019 -$95.3M -$68.4M -$18.5M -37% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-23
Q2 2019 -$76.8M -$54.2M -$8.49M -18.6% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-23
Q1 2019 -$68.3M $87.4M +$134M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-23
Q4 2018 -$202M -$60M -$22.1M -58.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$180M -$49.9M -$4.69M -10.4% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$175M -$45.7M -$2.39M -5.52% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$173M -$46.1M -$5.59M -13.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$167M -$37.9M -$8.94M -30.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$158M -$45.2M -$27.8M -160% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$130M -$43.3M -$29.3M -209% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$101M -$40.5M -$26M -178% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$75M -$29M -$15.8M -121% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-20
Q3 2016 -$59.1M -$17.4M -$4.6M -35.9% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-20
Q2 2016 -$54.5M -$14M -$1.64M -13.2% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-20
Q1 2016 -$52.9M -$14.6M -$3.12M -27.2% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-20
Q4 2015 -$49.8M -$13.1M -$3.67M -38.8% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-22
Q3 2015 -$46.1M -$12.8M -$3M -30.5% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-22
Q2 2015 -$43.1M -$12.4M -$3.16M -34.2% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-22
Q1 2015 -$40M -$11.5M -$3.59M -45.6% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-22
Q4 2014 -$36.4M -$9.46M +$233K +2.41% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-25
Q3 2014 -$36.6M -$9.81M -$4.57M -87.2% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-25
Q2 2014 -$32M -$9.24M -$2.32M -33.5% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-25
Q1 2014 -$29.7M -$7.87M -$3.64M -85.8% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-25
Q4 2013 -$26.1M -$9.69M -$6.91M -249% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-10
Q3 2013 -$19.2M -$5.24M -$1.89M -56.3% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-10
Q2 2013 -$17.3M -$6.92M -$3.75M -119% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-10
Q1 2013 -$13.5M -$4.24M -$1.79M -73.1% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-10
Q4 2012 -$11.7M -$2.78M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-13
Q3 2012 -$3.35M Jul 1, 2012 Sep 30, 2012 10-K 2014-03-13
Q2 2012 -$3.17M Apr 1, 2012 Jun 30, 2012 10-K 2014-03-13
Q1 2012 -$2.45M Jan 1, 2012 Mar 31, 2012 10-K 2014-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.